The purpose of the study is to evaluate the efficacy and toxicity of different timing of concurrent chemoradiation in the treatment of limited disease status Small-cell lung cancer.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
222
1. patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 \& Cisplatin 70mg/m2 D1. 2. radiotherapy start from day 1 of 1st chemotherapy cycle and complete 5250cGy/25fraction (daily one fraction, 210cGy).
1. patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 \& Cisplatin 70mg/m2 D1. 2. radiotherapy start from day 1 of the third cycle of EP chemotherapy and complete 5250cGy/25fraction (daily one fraction, 210cGy).
Keunchil Park
Seoul, South Korea
Asan Medican Center
Seoul, South Korea
complete response rate
Time frame: 6 months
overall survival
Time frame: 36 months
objective response rate
Time frame: 6 months
Progression-free survival
Time frame: 36 months
toxicity by NCI common toxicity version 2.0
Time frame: 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.